Literature DB >> 24659830

Relations among Three Parametric Multiple Testing Methods for Correlated Tests.

Changchun Xie1.   

Abstract

Multiple endpoints in clinical trials are usually correlated. To control the family-wise type I error rate, both Huque and Alosh's flexible fixed-sequence (FFS) testing method and Li and Mehrotra's adaptive alpha allocation approach (4A) have taken into account correlations among endpoints. I suggested a weighted multiple testing correction (WMTC) for correlated tests and compared it with FFS. However, the relationship between the 4A method and the FFS method or the relationship between the 4A method and the WMTC method has not been studied. In this paper, simulations are conducted to investigate these relationships. Tentative guidelines to help choosing an appropriate method are provided.

Entities:  

Keywords:  Bonferroni correction; Correlated endpoints; Fixed-sequence; Multivariate normal distribution; Weighted multiple testing correction

Year:  2014        PMID: 24659830      PMCID: PMC3959739          DOI: 10.1080/00949655.2012.729212

Source DB:  PubMed          Journal:  J Stat Comput Simul        ISSN: 0094-9655            Impact factor:   1.424


  5 in total

1.  Alpha calculus in clinical trials: considerations and commentary for the new millennium.

Authors:  L A Moyé
Journal:  Stat Med       Date:  2000-03-30       Impact factor: 2.373

2.  The fallback procedure for evaluating a single family of hypotheses.

Authors:  Brian L Wiens; Alexei Dmitrienko
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

3.  An efficient method for accommodating potentially underpowered primary endpoints.

Authors:  Jianjun Li; Devan V Mehrotra
Journal:  Stat Med       Date:  2008-11-20       Impact factor: 2.373

Review 4.  P-value interpretation and alpha allocation in clinical trials.

Authors:  L A Moyé
Journal:  Ann Epidemiol       Date:  1998-08       Impact factor: 3.797

5.  Weighted multiple testing correction for correlated tests.

Authors:  Changchun Xie
Journal:  Stat Med       Date:  2011-11-23       Impact factor: 2.373

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.